Cannabinoid and opioid interactions: Implications for opiate dependence and withdrawal

Neuroscience

Volumn 248, Issue , 2013, Pages 637-654

  Scavone, J L ^a   Sterling, R C ^a   Van Bockstaele, E J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Clinical; Endocannabinoid; Locus coeruleus; Marijuana; Norepinephrine; Stress

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANANDAMIDE; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ATROPINE PLUS DIPHENOXYLATE; CANNABINOID 1 RECEPTOR; CANNABIS; CLONIDINE; DEXANABINOL; DEXTROPROPOXYPHENE; DIAMORPHINE; DRONABINOL; ENDOCANNABINOID; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; LOFEXIDINE; METHADONE; MORPHINE; MU OPIATE RECEPTOR; NALTREXONE; NARCOTIC ANALGESIC AGENT; NORADRENALIN; OPIATE ANTAGONIST; OXYCODONE; PETHIDINE; RIMONABANT; SR 141716 A; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CHRONIC PAIN; CLINICAL FEATURE; CLINICAL PRACTICE; COGNITIVE DEFECT; CONNECTOME; CONVULSION; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG MISUSE; HEROIN DEPENDENCE; HUMAN; HYPOTENSION; LOCUS CERULEUS; MAINTENANCE THERAPY; MOLECULAR INTERACTION; MUSCLE SPASM; NARCOTIC DEPENDENCE; NAUSEA AND VOMITING; NEOPLASM; NEUROMODULATION; NONHUMAN; NORADRENERGIC SYSTEM; OPIATE ADDICTION; PRESCRIPTION; PRIORITY JOURNAL; RELAPSE; REVIEW; SEDATION; SIDE EFFECT; SOCIAL PROBLEM; STRESS; SUBSTITUTION THERAPY; TREMOR; WITHDRAWAL SYNDROME;

2-AG; 2-ARACHIDONOYLGLYCEROL; AC; ADENYLYL CYCLASE; CAMP RESPONSE ELEMENT BINDING PROTEIN; CANNABINOID TYPE 1 RECEPTORS; CB1R; CLINICAL; CORTICOTROPIN RELEASING FACTOR; CREB; CRF; EC; ENDOCANNABINOID; HPA; HYPOTHALAMIC-PITUITARY-ADRENAL; LC; LOCUS COERULEUS; MARIJUANA; METHADONE MAINTENANCE TREATMENT; MMT; MOR; MU-OPIOID RECEPTOR; NAC; NOREPINEPHRINE; NTS; NUCLEUS ACCUMBENS; NUCLEUS OF THE SOLITARY TRACT; PARAGIGANTOCELLULARIS; PGI; PKA; PROTEIN KINASE-A; STRESS; UDS; URINARY DRUG SCREEN;

ANALGESICS, OPIOID; ANIMALS; CANNABINOIDS; DRUG INTERACTIONS; ENDOCANNABINOIDS; HUMANS; LOCUS COERULEUS; NOREPINEPHRINE; OPIOID-RELATED DISORDERS; SIGNAL TRANSDUCTION; SUBSTANCE WITHDRAWAL SYNDROME; SYNAPSES;

EID: 84881367408     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.04.034     Document Type: Review

References (257)

1. Abercrombie E.D., Jacobs B.L. Single-unit response of noradrenergic neurons in the locus coeruleus of freely moving cats. II. Adaptation to chronically presented stressful stimuli. J Neurosci 1987, 7:2844-2848.
2. Aghajanian G.K., Kogan J.H., Moghaddam B. Opiate withdrawal increases glutamate and aspartate efflux in the locus coeruleus: an in vivo microdialysis study. Brain Res 1994, 636:126-130.
3. Aharonovich E., Liu X., Samet S., Nunes E., Waxman R., Hasin D. Postdischarge cannabis use and its relationship to cocaine, alcohol, and heroin use: a prospective study. Am J Psychiatry 2005, 162:1507-1514.
4. Akaoka H., Aston-Jones G. Opiate withdrawal-induced hyperactivity of locus coeruleus neurons is substantially mediated by augmented excitatory amino acid input. J Neurosci 1991, 11:3830-3839.
5. Alvarez V.A., Arttamangkul S., Dang V., Salem A., Whistler J.L., Von Zastrow M., Grandy D.K., Williams J.T. Mu-opioid receptors: ligand-dependent activation of potassium conductance, desensitization, and internalization. J Neurosci 2002, 22:5769-5776.
6. Arttamangkul S., Torrecilla M., Kobayashi K., Okano H., Williams J.T. Separation of mu-opioid receptor desensitization and internalization: endogenous receptors in primary neuronal cultures. J Neurosci 2006, 26:4118-4125.
7. Aston-Jones G., Bloom F.E. Nonrepinephrine-containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli. J Neurosci 1981, 1:887-900.
8. Aston-Jones G., Kalivas P.W. Brain norepinephrine rediscovered in addiction research. Biol Psychiatry 2008, 63:1005-1006.
9. Aston-Jones G., Ennis M., Pieribone V.A., Nickell W.T., Shipley M.T. The brain nucleus locus coeruleus: restricted afferent control of a broad efferent network. Science 1986, 234:734-737.
10. Aston-Jones G., Shipley M.T., Chouvet G., Ennis M., van Bockstaele E., Pieribone V., Shiekhattar R., Akaoka H., Drolet G., Astier B., et al. Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Prog Brain Res 1991, 88:47-75.
11. Barr J., Van Bockstaele E.J. Vesicular glutamate transporter-1 colocalizes with endogenous opioid peptides in axon terminals of the rat locus coeruleus. Anat Rec A Discov Mol Cell Evol Biol 2005, 284:466-474.
12. Barta W.D., Kurth M.E., Stein M.D., Tennen H., Kiene S.M. Craving and self-efficacy in the first five weeks of methadone maintenance therapy: a daily process study. J Stud Alcohol Drugs 2009, 70:735-740.
13. Basavarajappa B.S. Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Curr Neuropharmacol 2007, 5:81-97.
14. Berridge C.W., Waterhouse B.D. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev 2003, 42:33-84.
15. Birnbaum H.G., White A.G., Reynolds J.L., Greenberg P.E., Zhang M., Vallow S., Schein J.R., Katz N.P. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin J Pain 2006, 22:667-676.
16. Bosier B., Muccioli G.G., Hermans E., Lambert D.M. Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol 2010, 80:1-12.
17. Boundy V.A., Gold S.J., Messer C.J., Chen J., Son J.H., Joh T.H., Nestler E.J. Regulation of tyrosine hydroxylase promoter activity by chronic morphine in TH9.0-LacZ transgenic mice. J Neurosci 1998, 18:9989-9995.
18. Brewer D.D., Catalano R.F., Haggerty K., Gainey R.R., Fleming C.B. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction 1998, 93:73-92.
19. Brook J.S., Balka E.B., Whiteman M. The risks for late adolescence of early adolescent marijuana use. Am J Public Health 1999, 89:1549-1554.
20. Brook J.S., Adams R.E., Balka E.B., Johnson E. Early adolescent marijuana use: risks for the transition to young adulthood. Psychol Med 2002, 32:79-91.
21. Budney A.J., Moore B.A. Development and consequences of cannabis dependence. J Clin Pharmacol 2002, 42:28S-33S.
22. Budney A.J., Bickel W.K., Amass L. Marijuana use and treatment outcome among opioid-dependent patients. Addiction 1998, 93:493-503.
23. Cadoni C., Pisanu A., Solinas M., Acquas E., Di Chiara G. Behavioural sensitization after repeated exposure to delta 9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology 2001, 158:259-266.
24. Carrasco G.A., Van de Kar L.D. Neuroendocrine pharmacology of stress. Eur J Pharmacol 2003, 463:235-272.
25. Carvalho A.F., Van Bockstaele E.J. Direct intra-accumbal infusion of a beta-adrenergic receptor antagonist abolishes WIN 55,212-2-induced aversion. Neurosci Lett 2011, 500:82-85.
26. Carvalho A.F., Mackie K., Van Bockstaele E.J. Cannabinoid modulation of limbic forebrain noradrenergic circuitry. Eur J Neurosci 2010, 31:286-301.
27. Carvalho A.F., Reyes A.R., Sterling R.C., Unterwald E., Van Bockstaele E.J. Contribution of limbic norepinephrine to cannabinoid-induced aversion. Psychopharmacology 2010, 211:479-491.
28. Cassens G., Roffman M., Kuruc A., Orsulak P.J., Schildkraut J.J. Alterations in brain norepinephrine metabolism induced by environmental stimuli previously paired with inescapable shock. Science 1980, 209:1138-1140.
29. Chaperon F., Thiebot M.H. Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 1999, 13:243-281.
30. Cheng P.Y., Liu-Chen L.Y., Chen C., Pickel V.M. Immunolabeling of Mu opioid receptors in the rat nucleus of the solitary tract: extrasynaptic plasmalemmal localization and association with Leu5-enkephalin. J Comp Neurol 1996, 371:522-536.
31. Childers S.R., Fleming L., Konkoy C., Marckel D., Pacheco M., Sexton T., Ward S. Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann N Y Acad Sci 1992, 654:33-51.
32. Christie M.J., Williams J.T., North R.A. Mechanisms of tolerance to opiates in locus coeruleus neurons. NIDA Res Monogr 1987, 78:158-168.
33. Church S.H., Rothenberg J.L., Sullivan M.A., Bornstein G., Nunes E.V. Concurrent substance use and outcome in combined behavioral and naltrexone therapy for opiate dependence. Am J Drug Alcohol Abuse 2001, 27:441-452.
34. Cichewicz D.L. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004, 74:1317-1324.
35. Cichewicz D.L., McCarthy E.A. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther 2003, 304:1010-1015.
36. Cichewicz D.L., Welch S.P. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 2003, 305:812-817.
37. Cichewicz D.L., Martin Z.L., Smith F.L., Welch S.P. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther 1999, 289:859-867.
38. Cohen P.J. Medical marijuana: the conflict between scientific evidence and political ideology. Part one of two. J Pain Palliat Care Pharmacother 2009, 23:4-25.
39. Cohen P.J. Medical marijuana: the conflict between scientific evidence and political ideology. Part two of two. J Pain Palliat Care Pharmacother 2009, 23:120-140.
40. Cohen P.J. Medical marijuana 2010: it's time to fix the regulatory vacuum. J Law Med Ethics 2010, 38:654-666.
41. Corchero J., Avila M.A., Fuentes J.A., Manzanares J. Delta-9-tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. Life Sci 1997, 61:PL 39-43.
42. Corchero J., Fuentes J.A., Manzanares J. Delta 9-tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. Eur J Pharmacol 1997, 323:193-195.
43. Corchero J., Romero J., Berrendero F., Fernandez-Ruiz J., Ramos J.A., Fuentes J.A., Manzanares J. Time-dependent differences of repeated administration with delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen. Brain Res Mol Brain Res 1999, 67:148-157.
44. Corchero J., Manzanares J., Fuentes J.A. Cannabinoid/opioid crosstalk in the central nervous system. Crit Rev Neurobiol 2004, 16:159-172.
45. Corchero J., Oliva J.M., Garcia-Lecumberri C., Martin S., Ambrosio E., Manzanares J. Repeated administration with Delta9-tetrahydrocannabinol regulates mu-opioid receptor density in the rat brain. J Psychopharmacol 2004, 18:54-58.
46. Coven E., Ni Y., Widnell K.L., Chen J., Walker W.H., Habener J.F., Nestler E.J. Cell type-specific regulation of CREB gene expression: mutational analysis of CREB promoter activity. J Neurochem 1998, 71:1865-1874.
47. Cox M.L., Haller V.L., Welch S.P. Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat. Eur J Pharmacol 2007, 567:125-130.
48. Crawley J.N., Laverty R., Roth R.H. Clonidine reversal of increased norepinephrine metabolite levels during morphine withdrawal. Eur J Pharmacol 1979, 57:247-250.
49. Dang V.C., Williams J.T. Morphine-induced mu-opioid receptor desensitization. Mol Pharmacol 2005, 68:1127-1132.
50. De Vries T.J., Homberg J.R., Binnekade R., Raaso H., Schoffelmeer A.N. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology 2003, 168:164-169.
51. Degenhardt L., Hall W., Lynskey M. The relationship between cannabis use and other substance use in the general population. Drug Alcohol Depend 2001, 64:319-327.
52. Del Arco I., Navarro M., Bilbao A., Ferrer B., Piomelli D., Rodriguez De Fonseca F. Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor AM404. Eur J Pharmacol 2002, 454:103-104.
53. Demuth D.G., Molleman A. Cannabinoid signalling. Life Sci 2006, 78:549-563.
54. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 1995, 121:66-72.
55. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
56. Dhawan B.N., Cesselin F., Raghubir R., Reisine T., Bradley P.B., Portoghese P.S., Hamon M. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996, 48:567-592.
57. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994, 372:686-691.
58. Di Marzo V., De Petrocellis L., Bisogno T. The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb Exp Pharmacol 2005, 147-185.
59. Ding Y.Q., Kaneko T., Nomura S., Mizuno N. Immunohistochemical localization of mu-opioid receptors in the central nervous system of the rat. J Comp Neurol 1996, 367:375-402.
60. Dunn A.J., Swiergiel A.H., Palamarchouk V. Brain circuits involved in corticotropin-releasing factor-norepinephrine interactions during stress. Ann N Y Acad Sci 2004, 1018:25-34.
61. Ellgren M., Artmann A., Tkalych O., Gupta A., Hansen H.S., Hansen S.H., Devi L.A., Hurd Y.L. Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. Eur Neuropsychopharmacol 2008, 18:826-834.
62. Ellgren M., Spano S.M., Hurd Y.L. Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 2007, 32:607-615.
63. Ellner M. Marijuana use by heroin abusers as a factor in program retention. J Consult Clin Psychol 1977, 45:709-710.
64. Epstein D.H., Preston K.L. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction 2003, 98:269-279.
65. Farrell M. Opiate withdrawal. Addiction 1994, 89:1471-1475.
66. Fattore L., Cossu G., Spano M.S., Deiana S., Fadda P., Scherma M., Fratta W. Cannabinoids and reward: interactions with the opioid system. Crit Rev Neurobiol 2004, 16:147-158.
67. Fattore L., Deiana S., Spano S.M., Cossu G., Fadda P., Scherma M., Fratta W. Endocannabinoid system and opioid addiction: behavioural aspects. Pharmacol Biochem Behav 2005, 81:343-359.
68. Fattore L., Spano S., Cossu G., Deiana S., Fadda P., Fratta W. Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology 2005, 48:1097-1104.
69. Fattore L., Spano M.S., Deiana S., Melis V., Cossu G., Fadda P., Fratta W. An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives. Brain Res Rev 2007, 53:1-16.
70. Fattore L., Vigano D., Fadda P., Rubino T., Fratta W., Parolaro D. Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. Eur J Neurosci 2007, 25:2191-2200.
71. Fattore L., Fadda P., Spano M.S., Pistis M., Fratta W. Neurobiological mechanisms of cannabinoid addiction. Mol Cell Endocrinol 2008, 286:S97-S107.
72. Fernandez Espejo E., Cador M., Stinus L. Ethopharmacological analysis of naloxone-precipitated morphine withdrawal syndrome in rats: a newly-developed "etho-score". Psychopharmacology 1995, 122:122-130.
73. Fernandez-Ruiz J., Hernandez M., Ramos J.A. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 2010, 16:e72-91.
74. Ferry B., Roozendaal B., McGaugh J.L. Role of norepinephrine in mediating stress hormone regulation of long-term memory storage: a critical involvement of the amygdala. Biol Psychiatry 1999, 46:1140-1152.
75. Flugge G., Van Kampen M., Mijnster M.J. Perturbations in brain monoamine systems during stress. Cell Tissue Res 2004, 315:1-14.
76. Frederickson R.C., Hewes C.R., Aiken J.W. Correlation between the in vivo and an in vitro expression of opiate withdrawal precipitated by naloxone: their antagonism by l-(-)-delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 1976, 199:375-384.
77. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003, 83:1017-1066.
78. Fride E. Endocannabinoids in the central nervous system - an overview. Prostaglandins Leukot Essent Fatty Acids 2002, 66:221-233.
79. Funada M., Suzuki T., Sugano Y., Tsubai M., Misawa M., Ueda H., Misu Y. Role of beta-adrenoceptors in the expression of morphine withdrawal signs. Life Sci 1994, 54:PL 113-118.
80. Garcia-Arencibia M., Garcia C., Fernandez-Ruiz J. Cannabinoids and Parkinson's disease. CNS Neurol Disord Drug Targets 2009, 8:432-439.
81. Gellert V.F., Holtzman S.G. Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J Pharmacol Exp Ther 1978, 205:536-546.
82. Gerra G., Zaimovic A., Giusti F., Di Gennaro C., Zambelli U., Gardini S., Delsignore R. Lofexidine versus clonidine in rapid opiate detoxification. J Subst Abuse Treat 2001, 21:11-17.
83. Gilson A.M., Kreis P.G. The burden of the nonmedical use of prescription opioid analgesics. Pain Med 2009, 10(Suppl. 2):S89-100.
84. Gintzler A.R., Chakrabarti S. Post-opioid receptor adaptations to chronic morphine; altered functionality and associations of signaling molecules. Life Sci 2006, 79:717-722.
85. Giuffrida A., Beltramo M., Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 2001, 298:7-14.
86. Gold M.S. Opiate addiction and the locus coeruleus. The clinical utility of clonidine, naltrexone, methadone, and buprenorphine. Psychiatr Clin North Am 1993, 16:61-73.
87. Gold M.S., Redmond D.E., Kleber H.D. Noradrenergic hyperactivity in opiate withdrawal supported by clonidine reversal of opiate withdrawal. Am J Psychiatry 1979, 136:100-102.
88. Gorzalka B.B., Hill M.N., Hillard C.J. Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurosci Biobehav Rev 2008, 32:1152-1160.
89. Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 1988, 21:253-259.
90. Gottheil E., Sterling R.C., Weinstein S.P. Diminished illicit drug use as a consequence of long-term methadone maintenance. J Addict Dis 1993, 12:45-57.
91. Gowing L., Farrell M., Ali R., White J. Alpha2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2004, 18(4):CD002024.
92. Gowran A., Noonan J., Campbell V.A. The multiplicity of action of cannabinoids: implications for reating neurodegeneration. CNS Neurosci Ther. 2011, 17:637-644. 10.1111/j.1755-5949.2010.00195.x.
93. Gupta A., Mulder J., Gomes I., Rozenfeld R., Bushlin I., Ong E., Lim M., Maillet E., Junek M., Cahill C.M., Harkany T., Devi L.A. Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal 2010, 3:ra 54.
94. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991, 11:563-583.
95. Hermann D., Klages E., Welzel H., Mann K., Croissant B. Low efficacy of non-opioid drugs in opioid withdrawal symptoms. Addict Biol 2005, 10:165-169.
96. Hill M.N., Gorzalka B.B. Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress. Eur J Pharmacol 2004, 499:291-295.
97. Hill M.N., McEwen B.S. Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:791-797.
98. Hill M.N., Carrier E.J., Ho W.S., Shi L., Patel S., Gorzalka B.B., Hillard C.J. Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus. Hippocampus 2008, 18:221-226.
99. Hojo M., Sudo Y., Ando Y., Minami K., Takada M., Matsubara T., Kanaide M., Taniyama K., Sumikawa K., Uezono Y. Mu-opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci 2008, 108:308-319.
100. Hollister L.E. Health aspects of cannabis. Pharmacol Rev 1986, 38:1-20.
101. Houser S.J., Eads M., Embrey J.P., Welch S.P. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, delta(9)-THC and anandamide. Brain Res 2000, 857:337-342.
102. Howlett A.C., Bidaut-Russell M., Devane W.A., Melvin L.S., Johnson M.R., Herkenham M. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci 1990, 13:420-423.
103. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54:161-202.
104. Jasinski D.R. Opiate withdrawal syndrome: acute and protracted aspects. Ann N Y Acad Sci 1981, 362:183-186.
105. Jelsing J., Galzin A.M., Guillot E., Pruniaux M.P., Larsen P.J., Vrang N. Localization and phenotypic characterization of brainstem neurons activated by rimonabant and WIN55,212-2. Brain Res Bull 2009, 78:202-210.
106. Johnson A.D., Peoples J., Stornetta R.L., Van Bockstaele E.J. Opioid circuits originating from the nucleus paragigantocellularis and their potential role in opiate withdrawal. Brain Res 2002, 955:72-84.
107. Johnson E.E., Christie M.J., Connor M. The role of opioid receptor phosphorylation and trafficking in adaptations to persistent opioid treatment. Neurosignals 2005, 14:290-302.
108. Kearn C.S., Blake-Palmer K., Daniel E., Mackie K., Glass M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?. Mol Pharmacol 2005, 67:1697-1704.
109. Kendler K.S., Prescott C.A. Cannabis use, abuse, and dependence in a population-based sample of female twins. Am J Psychiatry 1998, 155:1016-1022.
110. Koob G.F., Maldonado R., Stinus L. Neural substrates of opiate withdrawal. Trends Neurosci 1992, 15:186-191.
111. Kreibich A., Reyes B.A., Curtis A.L., Ecke L., Chavkin C., Van Bockstaele E.J., Valentino R.J. Presynaptic inhibition of diverse afferents to the locus ceruleus by kappa-opiate receptors: a novel mechanism for regulating the central norepinephrine system. J Neurosci 2008, 28:6516-6525.
112. Kreitzer A.C., Regehr W.G. Retrograde signaling by endocannabinoids. Curr Opin Neurobiol 2002, 12:324-330.
113. Lane-Ladd S.B., Pineda J., Boundy V.A., Pfeuffer T., Krupinski J., Aghajanian G.K., Nestler E.J. CREB (cAMP response element-binding protein) in the locus coeruleus: biochemical, physiological, and behavioral evidence for a role in opiate dependence. J Neurosci 1997, 17:7890-7901.
114. Lichtman A.H., Sheikh S.M., Loh H.H., Martin B.R. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther 2001, 298:1007-1014.
115. Lobmaier P., Gossop M., Waal H., Bramness J. The pharmacological treatment of opioid addiction - a clinical perspective. Eur J Clin Pharmacol 2010, 66:537-545.
116. Lopez-Moreno J.A., Lopez-Jimenez A., Gorriti M.A., de Fonseca F.R. Functional interactions between endogenous cannabinoid and opioid systems: focus on alcohol, genetics and drug-addicted behaviors. Curr Drug Targets 2010, 11:406-428.
117. Lundqvist T. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav 2005, 81:319-330.
118. Machado Rocha F.C., Stefano S.C., De Cassia Haiek.R., Rosa Oliveira L.M., Da Silveira D.X. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) 2008, 17:431-443.
119. Mackie K. Cannabinoid receptor homo- and heterodimerization. Life Sci 2005, 77:1667-1673.
120. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 2005, 299-325.
121. Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 2008, 20(Suppl. 1):10-14.
122. Maldonado R. Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci Biobehav Rev 1997, 21:91-104.
123. Maldonado R. The neurobiology of addiction. J Neural Transm Suppl 2003, 1-14.
124. Maldonado R., Koob G.F. Destruction of the locus coeruleus decreases physical signs of opiate withdrawal. Brain Res 1993, 605:128-138.
125. Maldonado R., Valverde O. Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses. Eur Neuropsychopharmacol 2003, 13:401-410.
126. Maldonado R., Stinus L., Gold L.H., Koob G.F. Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther 1992, 261:669-677.
127. Maldonado R., Negus S., Koob G.F. Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta- and kappa-selective opioid antagonists. Neuropharmacology. 1992, 31:1231-1241.
128. Maldonado R., Valverde O., Garbay C., Roques B.P. Protein kinases in the locus coeruleus and periaqueductal gray matter are involved in the expression of opiate withdrawal. Naunyn Schmiedebergs Arch Pharmacol 1995, 352:565-575.
129. Mansour A., Fox C.A., Burke S., Akil H., Watson S.J. Immunohistochemical localization of the cloned mu opioid receptor in the rat CNS. J Chem Neuroanat 1995, 8:283-305.
130. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., Fuentes J.A. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Brain Res Mol Brain Res 1998, 55:126-132.
131. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 1999, 20:287-294.
132. Maremmani I., Stefania C., Pacini M., Maremmani A.G., Carlini M., Golia F., Deltito J., Dell'Osso L. Differential substance abuse patterns distribute according to gender in heroin addicts. J Psychoactive Drugs 2010, 42:89-95.
133. Mark T.L., Woody G.E., Juday T., Kleber H.D. The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001, 61:195-206.
134. Martin B.R., Mechoulam R., Razdan R.K. Discovery and characterization of endogenous cannabinoids. Life Sci 1999, 65:573-595.
135. Mas-Nieto M., Pommier B., Tzavara E.T., Caneparo A., Da Nascimento S., Le Fur G., Roques B.P., Noble F. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol 2001, 132:1809-1816.
136. Massi P., Vaccani A., Romorini S., Parolaro D. Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects. J Neuroimmunol 2001, 117:116-124.
137. McLaughlin R.J., Hill M.N., Gorzalka B.B. Monoaminergic neurotransmission contributes to cannabinoid-induced activation of the hypothalamic-pituitary-adrenal axis. Eur J Pharmacol 2009, 624:71-76.
138. Meader N. A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis. Drug Alcohol Depend 2010, 108:110-114.
139. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50:83-90.
140. Mechoulam R., Fride E., Di Marzo V. Endocannabinoids. Eur J Pharmacol 1998, 359:1-18.
141. Mendiguren A., Pineda J. Cannabinoids enhance N-methyl-d-aspartate-induced excitation of locus coeruleus neurons by CB1 receptors in rat brain slices. Neurosci Lett 2004, 363:1-5.
142. Mendiguren A., Pineda J. CB(1) cannabinoid receptors inhibit the glutamatergic component of KCl-evoked excitation of locus coeruleus neurons in rat brain slices. Eur J Pharmacol 2006, 534:83-88.
143. Mendiguren A., Pineda J. Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats. Eur J Pharmacol 2006, 534:83-88.
144. Mendiguren A., Pineda J. CB(1) cannabinoid receptors inhibit the glutamatergic component of KCl-evoked excitation of locus coeruleus neurons in rat brain slices. Neuropharmacology 2007, 52:617-625.
145. Moyse E., Marcel D., Leonard K., Beaudet A. Electron microscopic distribution of mu opioid receptors on noradrenergic neurons of the locus coeruleus. Eur J Neurosci 1997, 9:128-139.
146. Muntoni A.L., Pillolla G., Melis M., Perra S., Gessa G.L., Pistis M. Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons. Eur J Neurosci 2006, 23:2385-2394.
147. Musshoff F., Trafkowski J., Lichtermann D., Madea B. Comparison of urine results concerning co-consumption of illicit heroin and other drugs in heroin and methadone maintenance programs. Int J Legal Med. 2010, 124:499-503. 10.1007/s00414-009-0361-8.
148. Nava F., Manzato E., Lucchini A. Chronic cannabis use does not affect the normalization of hypothalamic-pituitary-adrenal (HPA) axis induced by methadone in heroin addicts. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1089-1094.
149. Navarro M., Carrera M.R., Fratta W., Valverde O., Cossu G., Fattore L., Chowen J.A., Gomez R., del Arco I., Villanua M.A., Maldonado R., Koob G.F., Rodriguez de Fonseca F. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 2001, 21:5344-5350.
150. Nestler E.J. Molecular mechanisms of drug addiction. J Neurosci 1992, 12:2439-2450.
151. Nestler E.J. Cellular responses to chronic treatment with drugs of abuse. Crit Rev Neurobiol 1993, 7:23-39.
152. Nestler E.J. Molecular neurobiology of addiction. Am J Addict 2001, 10:201-217.
153. Nestler E.J., Aghajanian G.K. Molecular and cellular basis of addiction. Science 1997, 278:58-63.
154. Nestler E.J., Erdos J.J., Terwilliger R., Duman R.S., Tallman J.F. Regulation of G proteins by chronic morphine in the rat locus coeruleus. Brain Res 1989, 476:230-239.
155. Nestler E.J., Alreja M., Aghajanian G.K. Molecular and cellular mechanisms of opiate action: studies in the rat locus coeruleus. Brain Res Bull 1994, 35:521-528.
156. Nestler E.J., Alreja M., Aghajanian G.K. Molecular control of locus coeruleus neurotransmission. Biol Psychiatry 1999, 46:1131-1139.
157. Nirenberg T.D., Liepman M.R., Cellucci T., Swift R.M., Sirota A.D. Cannabis versus other illicit drug use among methadone maintenance patients. Psychol Addict Behav 1996, 10:222-227.
158. Nixon L.N. Cannabis use and treatment outcome in methadone maintenance. Addiction 2003, 98:1321-1322. author reply 1322-1323.
159. North R.A., Williams J.T., Surprenant A., Christie M.J. Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. Proc Natl Acad Sci U S A 1987, 84:5487-5491.
160. Nurco D.N., Kinlock T.W., Hanlon T.E., Ball J.C. Nonnarcotic drug use over an addiction career - a study of heroin addicts in Baltimore and New York City. Compr Psychiatry 1988, 29:450-459.
161. OAS Analyses of substance abuse and treatment need issues 1998, Substance Abuse and Mental Health Services Administration. Office of Applied Studies, S. A. a. M. H. S. A. (Ed.).
162. OAS Results from the 2004 national survey on drug use and health: national findings. National survey on drug use and health 2005, Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services. Office of Applied Studies, S. A. a. M. H. S. A. (Ed.).
163. OAS Results from the 2008 national survey on drug use and health: national findings. National survey on drug use and health 2009, Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services. Office of Applied Studies, S. A. a. M. H. S. A., ed (Ed.).
164. Onaivi E.S. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int Rev Neurobiol 2009, 88:335-369.
165. Oropeza V.C., Page M.E., Van Bockstaele E.J. Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res 2005, 1046:45-54.
166. Oropeza V.C., Mackie K., Van Bockstaele E.J. Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Res 2007, 1127:36-44.
167. Page M.E., Valentino R.J. Locus coeruleus activation by physiological challenges. Brain Res Bull 1994, 35:557-560.
168. Page M.E., Oropeza V.C., Sparks S.E., Qian Y., Menko A.S., Van Bockstaele E.J. Repeated cannabinoid administration increases indices of noradrenergic activity in rats. Pharmacol Biochem Behav 2007, 86:162-168.
169. Page M.E., Oropeza V.C., Van Bockstaele E.J. Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex. Neurosci Lett 2008, 431:1-5.
170. Parolaro D., Rubino T., Vigano D., Massi P., Guidali C., Realini N. Cellular mechanisms underlying the interaction between cannabinoid and opioid system. Curr Drug Targets 2010, 11:393-405.
171. Pasternak G.W. Molecular biology of opioid analgesia. J Pain Symptom Manage 2005, 29:S2-9.
172. Patton G.C., Coffey C., Carlin J.B., Degenhardt L., Lynskey M., Hall W. Cannabis use and mental health in young people: cohort study. BMJ 2002, 325:1195-1198.
173. Pert C.B., Kuhar M.J., Snyder S.H. Opiate receptor: autoradiographic localization in rat brain. Proc Natl Acad Sci U S A 1976, 73:3729-3733.
174. Pickel V.M., Colago E.E. Presence of mu-opioid receptors in targets of efferent projections from the central nucleus of the amygdala to the nucleus of the solitary tract. Synapse 1999, 33:141-152.
175. Pickel V.M., Chan J., Kash T.L., Rodriguez J.J., MacKie K. Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience 2004, 127:101-112.
176. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003, 4:873-884.
177. Piomelli D. The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 2005, 6:672-679.
178. Piomelli D., Beltramo M., Giuffrida A., Stella N. Endogenous cannabinoid signaling. Neurobiol Dis 1998, 5:462-473.
179. Pugh G., Abood M.E., Welch S.P. Antisense oligodeoxynucleotides to the kappa-1 receptor block the antinociceptive effects of delta 9-THC in the spinal cord. Brain Res 1995, 689:157-158.
180. Pugh G., Smith P.B., Dombrowski D.S., Welch S.P. The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord. J Pharmacol Exp Ther 1996, 279:608-616.
181. Pugh G., Mason D.J., Combs V., Welch S.P. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. J Pharmacol Exp Ther 1997, 281:730-737.
182. Raby W.N., Carpenter K.M., Rothenberg J., Brooks A.C., Jiang H., Sullivan M., Bisaga A., Comer S., Nunes E.V. Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Am J Addict 2009, 18:301-308.
183. Ramirez B.G., Blazquez C., Gomez del Pulgar T., Guzman M., de Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005, 25:1904-1913.
184. Rasmussen K., Aghajanian G.K. Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: attenuation by lesions of the nucleus paragigantocellularis. Brain Res 1989, 505:346-350.
185. Rasmussen K., Beitner-Johnson D.B., Krystal J.H., Aghajanian G.K., Nestler E.J. Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical correlates. J Neurosci 1990, 10:2308-2317.
186. Reisfield G.M., Wasan A.D., Jamison R.N. The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature. Pain Med 2009, 10:1434-1441.
187. Reyes B.A., Glaser J.D., Van Bockstaele E.J. Ultrastructural evidence for co-localization of corticotropin-releasing factor receptor and mu-opioid receptor in the rat nucleus locus coeruleus. Neurosci Lett 2007, 413:216-221.
188. Reyes B.A., Chavkin C., van Bockstaele E.J. Subcellular targeting of kappa-opioid receptors in the rat nucleus locus coeruleus. J Comp Neurol 2009, 512:419-431.
189. Reyes B.A., Rosario J.C., Piana P.M., Van Bockstaele E.J. Cannabinoid modulation of cortical adrenergic receptors and transporters. J Neurosci Res 2009, 87:3671-3678.
190. Reyes B., Szot P., Sikkema C., Cathel A., Kirby L., Bockstaele E.V. Stress-induced sensitization of cortical adrenergic receptors following a history of cannabinoid exposure. Experimental Neurology 2012, 236:327-335. 10.1016/j.expneurol.2012.05.016.
191. Rios C.D., Jordan B.A., Gomes I., Devi L.A. G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Ther 2001, 92:71-87.
192. Rios C., Gomes I., Devi L.A. Mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 2006, 148:387-395.
193. Roberts J.D., Gennings C., Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 2006, 530:54-58.
194. Robledo P. Cannabinoids, opioids and MDMA: neuropsychological interactions related to addiction. Curr Drug Targets 2010, 11:429-439.
195. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 2001, 178:107-115.
196. Rodriguez J.J., Mackie K., Pickel V.M. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 2001, 21:823-833.
197. Rozenfeld R. Type I cannabinoid receptor trafficking: all roads lead to lysosome. Traffic 2010, 12(1):12-18. 10.1111/j.1600-0854.2010.01130.x.
198. Rubino T., Parolaro D. Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol 2008, 286:S108-113.
199. Rubino T., Massi P., Vigano D., Fuzio D., Parolaro D. Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome. Life Sci 2000, 66:2213-2219.
200. Salio C., Fischer J., Franzoni M.F., Mackie K., Kaneko T., Conrath M. CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. NeuroReport 2001, 12:3689-3692.
201. Sands S.A., Strong R., Corbitt J., Morilak D.A. Effects of acute restraint stress on tyrosine hydroxylase mRNA expression in locus coeruleus of Wistar and Wistar-Kyoto rats. Brain Res Mol Brain Res 2000, 75:1-7.
202. Sara S.J. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 2009, 10:211-223.
203. Saxon A.J., Calsyn D.A., Blaes P.A., Haver V.M., Greenberg D.M. Marijuana use by methadone maintenance patients. NIDA Res Monogr 1990, 105:306-307.
204. Saxon A.J., Calsyn D.A., Greenberg D., Blaes P., Haver V.M., Stanton V. Urine screening for marijuana among methadone-maintained patients. Am J Addict 1993, 2:207-211.
205. Scavone J.L., Van Bockstaele E.J. Mu-opioid receptor redistribution in the locus coeruleus upon precipitation of withdrawal in opiate-dependent rats. Anat Rec (Hoboken) 2009, 292:401-411.
206. Scavone J.L., Mackie K., Van Bockstaele E.J. Characterization of cannabinoid-1 receptors in the locus coeruleus: relationship with mu-opioid receptors. Brain Res 2010, 1312:18-31.
207. Scavone JL, Sterling R, Weinstein SP, Van Bockstaele E (2013) Impact of cannabis use during stabilization on methadone maintenance treatment. Am J Addict, in press, http://dx.doi.org/10.1111/j.1521-0391.2012.12044.x.
208. Schoffelmeer A.N., Hogenboom F., Wardeh G., De Vries T.J. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 2006, 51:773-781.
209. Shinba T., Ozawa N., Yoshii M., Yamamoto K. Delayed increase of brain noradrenaline after acute footshock stress in rats. Neurochem Res 2010, 35:412-417.
210. Singh M.E., Verty A.N., Price I., McGregor I.S., Mallet P.E. Modulation of morphine-induced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716. Neuropharmacology 2004, 47:1157-1169.
211. Smith P.A., Selley D.E., Sim-Selley L.J., Welch S.P. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol 2007, 571:129-137.
212. Solinas M., Panlilio L.V., Goldberg S.R. Exposure to delta-9-tetrahydrocannabinol (THC) increases subsequent heroin taking but not heroin's reinforcing efficacy: a self-administration study in rats. Neuropsychopharmacology 2004, 29:1301-1311.
213. Steffens S., Veillard N.R., Arnaud C., Pelli G., Burger F., Staub C., Karsak M., Zimmer A., Frossard J.L., Mach F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005, 434:782-786.
214. Steiner M.A., Wotjak C.T. Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Prog Brain Res 2008, 170:397-432.
215. Steiner M.A., Marsicano G., Wotjak C.T., Lutz B. Conditional cannabinoid receptor type 1 mutants reveal neuron subpopulation-specific effects on behavioral and neuroendocrine stress responses. Psychoneuroendocrinology 2008, 33:1165-1170.
216. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997, 388:773-778.
217. Stornetta R.L., Norton F.E., Guyenet P.G. Autonomic areas of rat brain exhibit increased Fos-like immunoreactivity during opiate withdrawal in rats. Brain Res 1993, 624:19-28.
218. Strang J., Bearn J., Gossop M. Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. Am J Addict 1999, 8:337-348.
219. Strassels S.A. Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm 2009, 15:556-562.
220. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995, 215:89-97.
221. Swann A.C., Elsworth J.D., Charney D.S., Jablons D.M., Roth R.H., Redmond D.E., Maas J.W. Brain catecholamine metabolites and behavior in morphine withdrawal. Eur J Pharmacol 1982, 86:167-175.
222. Szabo B., Schlicker E. Effects of cannabinoids on neurotransmission. Handb Exp Pharmacol 2005, 327-365.
223. Taylor J.R., Elsworth J.D., Garcia E.J., Grant S.J., Roth R.H., Redmond D.E. Clonidine infusions into the locus coeruleus attenuate behavioral and neurochemical changes associated with naloxone-precipitated withdrawal. Psychopharmacology 1988, 96:121-134.
224. Tempel A., Zukin R.S. Neuroanatomical patterns of the mu, delta, and kappa opioid receptors of rat brain as determined by quantitative in vitro autoradiography. Proc Natl Acad Sci U S A 1987, 84:4308-4312.
225. Terrillon S., Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep 2004, 5:30-34.
226. Tham S.M., Angus J.A., Tudor E.M., Wright C.E. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice. Br J Pharmacol 2005, 144:875-884.
227. Tucci S. Addiction and pain: cannabinoid and opioid interactions. Curr Drug Targets 2010, 11:392.
228. Valentino, R.J., Aston-Jones, G (1995) Physiological and anatomical determinants of locus coeruleus discharge: behavioral and clinical implications. In: Bloom F, Kupfer D (editors), Psychopharmacology: Fourth Generation of Progress. Raven Press, New York; p. 373-386.
229. Valentino R.J., Foote S.L., Aston-Jones G. Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus. Brain Res 1983, 270:363-367.
230. Valentino R.J., Foote S.L., Page M.E. The locus coeruleus as a site for integrating corticotropin-releasing factor and noradrenergic mediation of stress responses. Ann N Y Acad Sci 1993, 697:173-188.
231. Valentino R.J., Curtis A.L., Page M.E., Pavcovich L.A., Florin-Lechner S.M. Activation of the locus ceruleus brain noradrenergic system during stress: circuitry, consequences, and regulation. Adv Pharmacol 1998, 42:781-784.
232. Valverde O., Noble F., Beslot F., Dauge V., Fournie-Zaluski M.C., Roques B.P. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci 2001, 13:1816-1824.
233. Van Bockstaele E.J., Commons K.G. Internalization of mu-opioid receptors produced by etorphine in the rat locus coeruleus. Neuroscience 2001, 108:467-477.
234. Van Bockstaele E.J., Colago E.E., Cheng P., Moriwaki A., Uhl G.R., Pickel V.M. Ultrastructural evidence for prominent distribution of the mu-opioid receptor at extrasynaptic sites on noradrenergic dendrites in the rat nucleus locus coeruleus. J Neurosci 1996, 16:5037-5048.
235. Van Bockstaele E.J., Colago E.E., Moriwaki A., Uhl G.R. Mu-opioid receptor is located on the plasma membrane of dendrites that receive asymmetric synapses from axon terminals containing leucine-enkephalin in the rat nucleus locus coeruleus. J Comp Neurol 1996, 376:65-74.
236. Van Bockstaele E.J., Commons K., Pickel V.M. Delta-opioid receptor is present in presynaptic axon terminals in the rat nucleus locus coeruleus: relationships with methionine5-enkephalin. J Comp Neurol 1997, 388:575-586.
237. Van Bockstaele E.J., Peoples J., Menko A.S., McHugh K., Drolet G. Decreases in endogenous opioid peptides in the rat medullo-coerulear pathway after chronic morphine treatment. J Neurosci 2000, 20:8659-8666.
238. Van Bockstaele E.J., Menko A.S., Drolet G. Neuroadaptive responses in brainstem noradrenergic nuclei following chronic morphine exposure. Mol Neurobiol 2001, 23:155-171.
239. Van Bockstaele E.J., Qian Y., Sterling R.C., Page M.E. Low dose naltrexone administration in morphine dependent rats attenuates withdrawal-induced norepinephrine efflux in forebrain. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1048-1056.
240. Van Bockstaele E.J., Reyes B.A., Valentino R.J. The locus coeruleus: a key nucleus where stress and opioids intersect to mediate vulnerability to opiate abuse. Brain Res 2010, 1314:162-174.
241. Vela G., Ruiz-Gayo M., Fuentes J.A. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 1995, 34:665-668.
242. Vigano D., Valenti M., Cascio M.G., Di Marzo V., Parolaro D., Rubino T. Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine. Eur J Neurosci 2004, 20:1849-1857.
243. Vigano D., Rubino T., Parolaro D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav 2005, 81:360-368.
244. Vigano D., Rubino T., Vaccani A., Bianchessi S., Marmorato P., Castiglioni C., Parolaro D. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology 2005, 182:527-536.
245. Wasserman D.A., Weinstein M.G., Havassy B.E., Hall S.M. Factors associated with lapses to heroin use during methadone maintenance. Drug Alcohol Depend 1998, 52:183-192.
246. Weinshenker D., Schroeder J.P. There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacology 2007, 32:1433-1451.
247. Weinstein S.P., Gottheil E., Sterling R.C., DeMaria P.A. Long-term methadone maintenance treatment: some clinical examples. J Subst Abuse Treat 1993, 10:277-281.
248. Weizman T., Gelkopf M., Melamed Y., Adelson M., Bleich A. Cannabis abuse is not a risk factor for treatment outcome in methadone maintenance treatment: a 1-year prospective study in an Israeli clinic. Aust N Z J Psychiatry 2004, 38:42-46.
249. Welch S.P. Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry 2009, 21:143-151.
250. Welch S.P., Stevens D.L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 1992, 262:10-18.
251. Wesson D.R., Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs 2003, 35:253-259.
252. Widnell K.L., Russell D.S., Nestler E.J. Regulation of expression of cAMP response element-binding protein in the locus coeruleus in vivo and in a locus coeruleus-like cell line in vitro. Proc Natl Acad Sci U S A 1994, 91:10947-10951.
253. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science 2002, 296:678-682.
254. Witkin J.M., Tzavara E.T., Nomikos G.G. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol 2005, 16:315-331.
255. Wong M.L., Kling M.A., Munson P.J., Listwak S., Licinio J., Prolo P., Karp B., McCutcheon I.E., Geracioti T.D., DeBellis M.D., Rice K.C., Goldstein D.S., Veldhuis J.D., Chrousos G.P., Oldfield E.H., McCann S.M., Gold P.W. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Nat Acad Sci U S A 2000, 97:325-330.
256. Xu G.P., Van Bockstaele E., Reyes B., Bethea T., Valentino R.J. Chronic morphine sensitizes the brain norepinephrine system to corticotropin-releasing factor and stress. J Neurosci 2004, 24:8193-8197.
257. Yamaguchi T., Hagiwara Y., Tanaka H., Sugiura T., Waku K., Shoyama Y., Watanabe S., Yamamoto T. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res 2001, 909:121-126.